Multiple Myeloma

Celgene PASS

A non-interventional observational post authorisation safety study of subjects treated with lenalidomide

Merck Vorinostat 095

Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma after at least 2 prior treatment regimens

Merck Vorinostat 088

Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With relapsed or refractory  Multiple Myeloma

 

Myeloma XI

Myeloma IX is intended to be a unifying trial addressing issues in patients of all ages and providing

a strategy within which to introduce new treatments as they become available. There are, however,

two distinct treatment pathways.

i) Intensive pathway:

 

For younger/fitter patients where intensive HDT with stem cell support

ii) Non-intensive pathway:

considered appropriate.

Although the previous MRC Myeloma VII trial, in which there was randomisation to HDT, was

restricted to patients under the age of 65, it is recognised that fit patients over this age may wish to

receive the more intensive treatment, and the decision with regard to which pathway to follow will

be a matter for discussion between the treating clinician and the patient.

For older/less fit patients where standard dose chemotherapy is

is considered appropriate.